Curium Acquires Abscint SA (ABS-011) to Expand HER2 PET Radiodiagnostic Pipeline

Curium, a global radiopharmaceutical company, completed its acquisition of Abscint SA, a Belgian clinical-stage molecular imaging company. The deal gives Curium the global rights to develop, manufacture, and commercialize ABS-011, a Phase 2b gallium-68-labeled HER2-targeting PET radiodiagnostic tracer currently evaluated in the HERMIA trial in Belgium.